These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 10366815)

  • 1. New drug makes host cell machinery unavailable to HIV.
    Senior K
    Mol Med Today; 1999 Jun; 5(6):234-5. PubMed ID: 10366815
    [No Abstract]   [Full Text] [Related]  

  • 2. Benefits from early treatment of HIV-1 infection.
    Klein D
    Trends Mol Med; 2001 Jan; 7(1):9. PubMed ID: 11427995
    [No Abstract]   [Full Text] [Related]  

  • 3. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques.
    Ambrose Z; Boltz V; Palmer S; Coffin JM; Hughes SH; Kewalramani VN
    J Virol; 2004 Dec; 78(24):13553-61. PubMed ID: 15564466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A quantitative measurement of antiviral activity of anti-human immunodeficiency virus type 1 drugs against simian immunodeficiency virus infection: dose-response curve slope strongly influences class-specific inhibitory potential.
    Deng K; Zink MC; Clements JE; Siliciano RF
    J Virol; 2012 Oct; 86(20):11368-72. PubMed ID: 22875968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PMPA--first human results.
    James JS
    AIDS Treat News; 1997 Apr; (No 269):3, 6. PubMed ID: 11364254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug flushes out hidden AIDS virus.
    Cohen J
    Science; 2015 Mar; 347(6226):1056. PubMed ID: 25745141
    [No Abstract]   [Full Text] [Related]  

  • 7. Neuroprotective and anti-human immunodeficiency virus activity of minocycline.
    Zink MC; Uhrlaub J; DeWitt J; Voelker T; Bullock B; Mankowski J; Tarwater P; Clements J; Barber S
    JAMA; 2005 Apr; 293(16):2003-11. PubMed ID: 15855434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early HIV infection in vivo: branching-process model for studying timing of immune responses and drug therapy.
    Wick D; Self SG
    Math Biosci; 2000 Jun; 165(2):115-34. PubMed ID: 10854614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques.
    Hazuda DJ; Young SD; Guare JP; Anthony NJ; Gomez RP; Wai JS; Vacca JP; Handt L; Motzel SL; Klein HJ; Dornadula G; Danovich RM; Witmer MV; Wilson KA; Tussey L; Schleif WA; Gabryelski LS; Jin L; Miller MD; Casimiro DR; Emini EA; Shiver JW
    Science; 2004 Jul; 305(5683):528-32. PubMed ID: 15247437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Anti-HIV therapeutic approaches in animal models].
    Dormont D
    Rev Med Interne; 2002 Dec; 23 Suppl 5():532s-534s. PubMed ID: 12701243
    [No Abstract]   [Full Text] [Related]  

  • 11. Nonhuman primate models for HIV cure research.
    Apetrei C; Pandrea I; Mellors JW
    PLoS Pathog; 2012; 8(8):e1002892. PubMed ID: 22956905
    [No Abstract]   [Full Text] [Related]  

  • 12. AIDS research. New drug shows promise in monkeys.
    Cohen J
    Science; 1995 Nov; 270(5239):1121-2. PubMed ID: 7502035
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacoresistance: an emerging clinical problem.
    Carosi G
    J Biol Regul Homeost Agents; 1998; 12(1-2 Suppl):9-14. PubMed ID: 9689572
    [No Abstract]   [Full Text] [Related]  

  • 14. Development of virus-specific immune responses in SHIV(KU)-infected macaques treated with PMPA.
    Kumar A; Buch S; Foresman L; Bischofberger N; Lifson JD; Narayan O
    Virology; 2001 Jan; 279(1):97-108. PubMed ID: 11145893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymph nodes harbor viral reservoirs that cause rebound of plasma viremia in SIV-infected macaques upon cessation of combined antiretroviral therapy.
    Horiike M; Iwami S; Kodama M; Sato A; Watanabe Y; Yasui M; Ishida Y; Kobayashi T; Miura T; Igarashi T
    Virology; 2012 Feb; 423(2):107-18. PubMed ID: 22196013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of a CCR5 inhibitor on viral loads in macaques dual-infected with R5 and X4 primate immunodeficiency viruses.
    Wolinsky SM; Veazey RS; Kunstman KJ; Klasse PJ; Dufour J; Marozsan AJ; Springer MS; Moore JP
    Virology; 2004 Oct; 328(1):19-29. PubMed ID: 15380354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Administration of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) for prevention of perinatal simian immunodeficiency virus infection in rhesus macaques.
    Van Rompay KK; Marthas ML; Lifson JD; Berardi CJ; Vasquez GM; Agatep E; Dehqanzada ZA; Cundy KC; Bischofberger N; Pedersen NC
    AIDS Res Hum Retroviruses; 1998 Jun; 14(9):761-73. PubMed ID: 9643376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Animal models used for the evaluation of antiretroviral therapies.
    Dias AS; Bester MJ; Britz RF; Apostolides Z
    Curr HIV Res; 2006 Oct; 4(4):431-46. PubMed ID: 17073618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of virus load by highly active antiretroviral therapy in rhesus macaques infected with a recombinant simian immunodeficiency virus containing reverse transcriptase from human immunodeficiency virus type 1.
    North TW; Van Rompay KK; Higgins J; Matthews TB; Wadford DA; Pedersen NC; Schinazi RF
    J Virol; 2005 Jun; 79(12):7349-54. PubMed ID: 15919889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Antiviral Activity of the Cellular Glycoprotein LGALS3BP/90K Is Species Specific.
    Lodermeyer V; Ssebyatika G; Passos V; Ponnurangam A; Malassa A; Ewald E; Stürzel CM; Kirchhoff F; Rotger M; Falk CS; Telenti A; Krey T; Goffinet C
    J Virol; 2018 Jul; 92(14):. PubMed ID: 29743357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.